| Product Name | MF | CAS | Details |
|---|
| 5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE, 10 mM in DMSO | C8H13N3S | 17899-49-9 | Details |
| NVP-TAE 684, 10 mM in DMSO | C30H40ClN7O3S | 761439-42-3 | Details |
| 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate, 10 mM in DMS | C26H31N3O8 | 239463-85-5 | Details |
| Taladegib | C26H24F4N6O | 1258861-20-9 | Details |
| TAK-901 | C28H32N4O3S | 934541-31-8 | Details |
| (S)-2-((R)-3-(4-chlorophenyl)-N’-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-methylbutanamide, | C27H27Cl2N5O3S | 1404117-65-2 | Details |
| Tanzisertib, 10 mM in DMSO | C21H23F3N6O2 | 899805-25-5 | Details |
| TAK-071, 10 mM in DMSO | C24H24FN3O3 | 1820812-16-5 | Details |
| Subasumstat, 10 mM in DMSO | C25H28ClN5O5S2 | 1858276-04-6 | Details |
| Thalidomide-NH-C2-PEG3-OH | C21H27N3O8 | 2140807-23-2 | Details |
| Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]-, 10 mM in DMSO | C19H16O5 | 91627-33-7 | Details |
| GR103545, 10 mM in DMSO | C23H29Cl2N3O7 | 126766-43-6 | Details |
| Tarloxotinib bromide, 10 mM in DMSO | C24H24Br2ClN9O3 | 1636180-98-7 | Details |
| Takeda103A, 10 mM in DMSO | C24H23F2N7O | 865609-72-9 | Details |
| 8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid | C19H21N3O2 | 816450-73-4 | Details |
| GP130 receptor agonist-1, 10 mM in DMSO | C15H11FN2S | 339303-87-6 | Details |
| TAK-615, 10 mM in DMSO | C25H22FNO4 | 1664335-55-0 | Details |
| TAK-020, 10 mM in DMSO | C18H17N5O3 | 1627603-21-7 | Details |
| Tafetinib | C24H29FN4O2 | 1032265-57-8 | Details |
| gamma-preprotachykinin amide (72-92) acetate | Details |
| 3-(7,7-dimethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)-1H-indole-7-carbonitrile, 10 mM in DMSO | C18H14N4O | 2759137-87-4 | Details |
| ethyl 1-[(4-cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1H-imidazole-5-carboxylate, 10 mM in DMSO | C22H18N4O3 | 2738381-94-5 | Details |
| (3Z)-1-methyl-3-[2-(4-methylphenyl)-2-oxo-ethylidene]piperazin-2-one, 10 mM in DMSO | C14H16N2O2 | 178408-16-7 | Details |
| (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate | Details |
| 5-(3-bromo-4,5-dihydroisoxazol-5-yl)-3-(4-(tert-butyl)phenyl)-1,2,4-oxadiazole, 10 mM in DMSO | 2863687-18-5 | Details |
| TA-03, 10 mM in DMSO | C14H16N2O | 5778-80-3 | Details |
| NVP-TAE 226, 10 mM in DMSO | C23H25ClN6O3 | 761437-28-9 | Details |
| Targocil, 10 mM in DMSO | C21H22ClN5O4S | 1200443-21-5 | Details |
| TAK-243, 10 mM in DMSO | C19H20F3N5O5S2 | 1450833-55-2 | Details |
| 5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | C13H9BrN2O4 | 26166-92-7 | Details |
| LY3405105 | C26H39N7O3 | 2326428-25-3 | Details |
| GPR34 receptor antagonist 2, 10 mM in DMSO | C31H26ClNO4 | 907952-06-1 | Details |
| TAK-653 | C19H23N3O3S | 1358751-06-0 | Details |
| MAT2A inhibitor 4, 10 mM in DMSO | C16H15ClFN | 1391934-91-0 | Details |
| N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-bromoaniline, 10 mM in DMSO | C22H18BrN7 | 1352608-94-6 | Details |
| 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid, 10 mM in DMSO | C16H13FN2O3 | 452105-33-8 | Details |
| TAK-733, 10 mM in DMSO | C17H15F2IN4O4 | 1035555-63-5 | Details |
| 4-[(E)-{[4,6-Di(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazono}methy l]-2,6-dimethoxyphenol, 10 mM in DMSO | C20H27N7O5 | 321557-16-8 | Details |
| 5-Pyrimidinecarboxamide, 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-, rel-, 10 mM in DMSO | C19H23N9O | 1194954-52-3 | Details |
| Taltirelin acetate, 10 mM in DMSO | C19H27N7O7 | 1549593-23-8 | Details |
| Talabostat mesylate, 10 mM in DMSO | C10H23BN2O6S | 150080-09-4 | Details |
| Fasiglifam, 10 mM in DMSO | C29H32O7S | 1000413-72-8 | Details |
| 4-(6,7-dimethoxyquinolin-4-yl)oxyaniline, 10 mM in DMSO | C17H16N2O3 | 190728-25-7 | Details |
| TAK-593, 10 mM in DMSO | C23H23N7O3 | 1005780-62-0 | Details |
| TAK-632, 10 mM in DMSO | C27H18F4N4O3S | 1228591-30-7 | Details |
| Tanimilast | C30H30Cl2F2N2O8S | 1239278-59-1 | Details |
| TA-01, 10 mM in DMSO | C20H12F3N3 | 1784751-18-3 | Details |
| Taminadenant, 10 mM in DMSO | C10H8BrN7 | 1337962-47-6 | Details |
| 4-QUinolinecarboxamide, N-[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]phenyl]-1,2-dihydro-2-oxo-, 10 mM in DMSO | C25H22N4O5S | 939760-13-1 | Details |
| TAS0728, 10 mM in DMSO | C26H32N8O3 | 2088323-16-2 | Details |
| C/EBPα inducer 1 | C20H12FN3O4 | 2374285-52-4 | Details |
| SCR130, 10 mM in DMSO | C19H13Cl2N3O2S | 2377858-38-1 | Details |
| AG-270, 10 mM in DMSO | C30H27N5O2 | 2201056-66-6 | Details |
| Piperazine, 1-(4-fluorophenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-, 10 mM in DMSO | C20H25FN2O3 | 80305-11-9 | Details |
| Pomalidomide-PEG3-OH | C19H23N3O7 | 2140807-36-7 | Details |
| 2-(2,6-dioxopiperidin-3-yl)-4-((9-hydroxynonyl)oxy)isoindoline-1,3-dione | C22H28N2O6 | 2619511-72-5 | Details |
| Talampanel, 10 mM in DMSO | C19H19N3O3 | 161832-65-1 | Details |
| (1S,4R)-N-Desmethyl Sertraline Hydrochloride, 10 mM in DMSO | C16H16Cl3N | 675126-07-5 | Details |
| Fosravuconazole L-lysine ethanolate | C31H40F2N7O8PS | 914361-45-8 | Details |
| TAK-960, 10 mM in DMSO | C27H34F3N7O3 | 1137868-52-0 | Details |
| Takeda-6d, 10 mM in DMSO | C27H19ClFN5O3S | 1125632-93-0 | Details |
| Targapremir-210 | C32H36N10O2 | 1049722-30-6 | Details |
| Balipodect, 10 mM in DMSO | C23H17FN6O2 | 1238697-26-1 | Details |
| TAI-1, 10 mM in DMSO | C24H21N3O3S | 1334921-03-7 | Details |
| Dazonone, 10 mM in DMSO | C11H10ClN3O | 105622-85-3 | Details |
| TAK-659 hydrochloride | C17H22ClFN6O | 1952251-28-3 | Details |
| N-Cyclohexyl-4-[1-(1-piperazinyl)-2,6-naphthyridin-3-yl]-2-pyridinamine | C23H28N6 | 1071135-06-2 | Details |
| TAK-715, 10 mM in DMSO | C24H21N3OS | 303162-79-0 | Details |
| TAK-418, 10 mM in DMSO | 1818252-53-7 | Details |
| NSC 73150, 10 mM in DMSO | C12H12N4O2 | 66680-03-3 | Details |
| Talnetant, 10 mM in DMSO | C25H22N2O2 | 174636-32-9 | Details |
| TAK-779, 10 mM in DMSO | C33H39N2O2.Cl | 229005-80-5 | Details |
| N,N,O-Tridesmethylvenlafaxine, 10 mM in DMSO | C14H21NO2 | 149289-29-2 | Details |
| TAK-285, 10 mM in DMSO | C26H25ClF3N5O3 | 871026-44-7 | Details |
| Taprenepag, 10 mM in DMSO | C24H22N4O5S | 752187-80-7 | Details |
| TAK-441 | C28H31F3N4O6 | 1186231-83-3 | Details |
| T-900607, 10 mM in DMSO | C14H10F5N3O4S | 261944-52-9 | Details |
| TAO Kinase inhibitor 1, 10 mM in DMSO | C25H24N2O2 | 850467-66-2 | Details |
| N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyrazine-2-carboxamide, 10 mM in DMSO | C14H12N4OS | 312508-42-2 | Details |
| TAK-041, 10 mM in DMSO | C18H15F3N4O3 | 1929519-13-0 | Details |
| TAM-IN-2 | C31H27F2N7O3 | 2135642-56-5 | Details |
| Exo-1, 10 mM in DMSO | C15H12FNO3 | 461681-88-9 | Details |
| Thalidomide-PEG4-Propargyl | C24H28N2O9 | 2098799-77-8 | Details |
| Benzonitrile, 3,3''-[(2-oxo-1,3-cyclohexanediylidene)dimethylidyne]bis- (9CI), 10 mM in DMSO | C22H16N2O | 63476-70-0 | Details |
| EAAT2 activator 1, 10 mM in DMSO | C16H11ClFN3S | 892415-28-0 | Details |
| (E)-3-(3,4-dichlorophenyl)-N-(2-(4-(methylsulfonyl)piperazin-1-yl)-2-oxoethyl)acrylamide, 10 mM in DMSO | C16H19Cl2N3O4S | 2505001-62-5 | Details |
| 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl methanesulfonate, 10 mM in DMSO | C11H13F3O5S | 160969-03-9 | Details |
| KCNQ2/3 activator-1, 10 mM in DMSO | C23H29FN2O | 1009344-33-5 | Details |
| TA-02, 10 mM in DMSO | C20H13F2N3 | 1784751-19-4 | Details |
| Takinib, 10 mM in DMSO | C18H18N4O2 | 1111556-37-6 | Details |
| 1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID, 10 mM in DMSO | C13H13NO5 | 260555-42-8 | Details |
| Tabernanthalog, 10 mM in DMSO | C14H18N2O | 2483829-58-7 | Details |
| Pomalidomide-PEG2-OH | C17H19N3O6 | 2143097-10-1 | Details |
| Thalidomide-NH-PEG1-NH2 hydrochloride | C17H21ClN4O5 | 2154342-56-8 | Details |
| 2H-Imidazo[4,5-b]pyrazin-2-one, 1,3-dihydro-6-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-, 10 mM | C19H23N5O3 | 1021917-65-6 | Details |
| Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)-rel-, 10 mM in DMSO | C18H18O3 | 533883-77-1 | Details |
| 3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide, 10 mM in DMSO | C28H24ClN3O6 | 246238-55-1 | Details |
| TAE-1 | C39H51I3N6O9 | 1414469-59-2 | Details |
| Taprizosin | C25H26N6O4S | 210538-44-6 | Details |
| 2-(2,6-dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)oxy)isoindoline-1,3-dione | C20H24N2O6 | 2093536-10-6 | Details |
| Product Total： Product Page： | ||||
| 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 | ||||